The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases

Table 3

Binary logistic regression evaluating the accuracy of GLYCOV and CA125 using the cut-off values of 0.63 and 35 kU/L, respectively. (a) Early-stage EOC versus controls; (b) early-stage EOC versus patients suffering from benign ovarian diseases.

(a)

	Prediction model
	EOC/healthy		Sensitivity/specificity
	0	1
GLYCOV
EOC	1	19	0.95
Healthy controls	32	1	0.97
CA125
EOC	8	12	0.60
Healthy controls	32	1	0.97
Combined
EOC	1	19	0.95
Healthy controls	32	1	0.97

(b)

	Prediction model
	EOC/BOD		Sensitivity/specificity
	0	1
GLYCOV
EOC	1	19	0.95
BOD	16	4	0.80
CA125
EOC	8	12	0.60
BOD	13	7	0.65
Combined
EOC	1	19	0.95
BOD	18	2	0.90